Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DIGI Group
Amsterdam, North Holland, Netherlandsthedigigroup.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Commercial
01
Overview
Digi.Bio develops advanced lab-on-a-chip and artificial intelligence-powered platforms that automate, miniaturize, and accelerate biologic development—especially cell therapies—by enabling high-content single-cell analysis. Their Desktop Biofoundry allows rapid cytotoxicity testing, real-time data tracking, automated workflows, and deep insights into therapy efficacy at the single-cell level. This enables faster R&D cycles with reduced material waste.
- Modalities
- Cell therapyDigital microfluidics platform
- Industry
- Drug Discovery Services
02
Partnerships
Merck AcceleratorHAX Accelerator/SOSV
Beyond the preview
Go deeper on DIGI Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIGI Group.